VB10.16

PreclinicalBiologic

VB10.16 is one of 4 biologic programs targeting HPV Positive Oropharyngeal Squamous Cell Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HPV Positive Oropharyngeal Squamous Cell CarcinomaRecruiting

HPV Positive Oropharyngeal Squamous Cell CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in HPV Positive Oropharyngeal Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Preclinical

1 2

Cisplatin Chemotherapy

GSK

Phase 2

1 3

VB10.16

NNykode Therapeutics ASA

Preclinical

1 4

ATRN-119

AAprea Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

HPV Positive Oropharyngeal Squamous Cell Carcinoma

NCT06016920

Clinical

Trials by Indication[1]

Cervical Cancer2 trials

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Withdrawn·NNykode Therapeutics ASA·Phase 2·NCT06099418

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Completed·NNykode Therapeutics ASA·Phase 2·NCT04405349·52 enrolled

Immunogenicity1 trial

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

Completed·NNykode Therapeutics ASA·Phase 1/2·NCT02529930·34 enrolled

HPV Positive Oropharyngeal Squamous Cell Carcinoma1 trial

A Phase 1/2, Open-label Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 in Combination With Pembrolizumab in Patients With Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squamous Cell Carcinoma

Recruiting·NNykode Therapeutics ASA·Preclinical·NCT06016920·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for VB10.16. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VB10.16 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VB10.16. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nykode Therapeutics ASA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: NNykode Therapeutics ASA

VB10.16

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Cervical Cancer2 trials

Immunogenicity1 trial

HPV Positive Oropharyngeal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News